Drug Approval | February 14, 2022
Lilly's bebtelovimab receives EUA to treat mild-to-moderate Covid-19
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)
The partnership includes multiple collaboration areas and is an important milestone for bringing cost-competitive biobased products to the market, with applications in the pharmaceutical, agricultural, cosmetics and personal care, and automotive industries
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
The need is to vaccinate people who have not contracted Covid-19
Subscribe To Our Newsletter & Stay Updated
